MDMA-Assisted Therapy: Closeness Predicts Social Anxiety Outcomes

MDMA-Assisted Therapy: Closeness During Sessions Predicts Social Anxiety Outcomes

Perceived therapist-patient closeness during MDMA-assisted therapy (MDMA-AT) sessions predicts improved outcomes in social anxiety disorder (SAD), according to a preregistered pilot trial published on September 11, 2026 (OpenAlex). This study, conducted with 20 participants diagnosed with SAD, provides the first empirical evidence that dynamic interpersonal closeness—distinct from the more stable therapeutic alliance—plays a critical role in the efficacy of MDMA-AT for social anxiety.

Mechanism: Distinguishing Alliance from Dynamic Closeness in MDMA-AT

Therapeutic alliance, typically considered a stable foundation of psychotherapy, was assessed using the Agnew Relationship Measure before and after MDMA dosing sessions. The study also measured perceived interpersonal closeness using the Inclusion of Other in the Self Scale. Results showed that while therapeutic alliance was high after preparatory sessions and increased after the first MDMA session, it reached a ceiling, showing little further change. In contrast, perceived closeness surged during each MDMA session and receded in the following non-drug intervals.

Crucially, greater closeness during MDMA sessions predicted lower post-treatment social anxiety, even after controlling for pre-session closeness. The study also found that self-transcendent emotions—such as feelings of unity or connection—were linked to higher closeness during MDMA sessions. Notably, pre-dosing closeness predicted the intensity of self-transcendent experiences, suggesting a bidirectional relationship between relational context and acute psychedelic effects. This distinction between alliance and closeness offers a new lens for understanding the relational mechanisms underpinning psychedelic-assisted therapies.

Implications for Clinical Trial Design and Therapist Training

These findings have immediate implications for the design of future clinical trials and the training of therapists in psychedelic-assisted psychotherapy. The dynamic nature of closeness, as opposed to the relatively static alliance, suggests that session-specific relational processes may be more sensitive predictors of patient outcomes. Trial protocols may benefit from incorporating repeated, session-level assessments of closeness, rather than relying solely on global alliance measures.

For therapist training, the results underscore the importance of fostering real-time interpersonal connection during dosing sessions. This could involve specific training modules focused on presence, attunement, and managing the ebb and flow of closeness, especially as patients navigate intense emotional states. As MDMA-AT moves toward larger, multisite trials and potential regulatory approval, these process-level insights could inform best practices and therapist competencies, potentially standardizing relational skills as a core element of psychedelic therapy certification.

Risks, Limitations, and Unknowns

While the study provides valuable process data, several limitations temper its generalizability. The trial was open-label, lacked a control group, and included only 20 participants, limiting statistical power and the ability to disentangle MDMA-specific effects from expectancy or therapist factors. The measurement of closeness is inherently subjective and may be influenced by social desirability or acute drug effects. Additionally, the study does not address potential risks of excessive or inappropriate closeness, such as boundary violations or emotional overdependence, which are recognized concerns in psychedelic therapy settings.

Another underexplored risk is the potential for therapist variability: if closeness is a key mediator of outcome, differences in therapist style or skill could introduce significant variability in results across sites or practitioners. This may complicate efforts to scale MDMA-AT or ensure fidelity in real-world settings. Regulatory bodies and training organizations will need to balance the encouragement of authentic connection with robust safeguards and supervision to mitigate relational risks.

Looking Forward: Integrating Relational Metrics into Psychedelic Research

The identification of dynamic closeness as a predictor of outcome in MDMA-AT for SAD marks a shift toward more granular, process-oriented research in psychedelic science. Future trials—especially pivotal Phase 3 studies and implementation research—may include session-level relational metrics as secondary or exploratory endpoints. This approach could help clarify the mechanisms of change in psychedelic therapies and inform adaptive trial designs that optimize both safety and efficacy.

For regulators, funders, and clinical operators, the study highlights the need to invest in therapist training, ongoing supervision, and process monitoring as MDMA-AT moves toward broader adoption. As the field matures, integrating relational science with pharmacological and neurobiological research will be essential for developing safe, effective, and scalable psychedelic-assisted interventions.

How we research: This article was written and reviewed by Dr. Alex S. Meyer, PhD (clinical psychology, psychedelic process research), on 2026-09-15. Primary sources include the original pilot trial publication and associated clinical trial registry entries.